Demonstrating your compound’s proof-of-concept is an important developmental milestone. If you can show compelling, valid data supporting the safety, efficacy and commercial potential of your molecule at this stage, you can:
- Optimize the market value of your compound
- Enhance your ability to meet your drug development goals
- Meet the demands of regulators, providers and patients
As R&D expenditures in Asia-Pac continue to increase, Dr. Gries’ presentation will examine the five ways to maximize molecule value. He will provide practical advice on reaching your proof-of-concept milestones.
- Medicalization of early phase clinical development
- Biomarkers and pharmacogenomics
- Risk-based drug development
- Commercial valuation
- Working with external partners
Jean-Michel Gries, PharmD PhD MBA FCP, VP & GM, Early Clinical Development, Covance
Dr. Jean-Michel Gries is Vice President and GM of Early Clinical Development, an organization dedicated to help companies achieve their major clinical and investment decision through efficient Proof-of-Concept and early in-patient studies.
Prior to joining Covance, Dr. Gries was the Head of R&D for Pharmaceutical products at Alcon (a Novartis Company), in which capacity he led the transformation of the organization to support more innovative mechanism of actions for the treatment of ocular diseases. Prior to Alcon, Dr. Gries was the US Head of Clinical Pharmacology for Hoffmann-La Roche. Dr. Gries started his career as a director of clinical pharmacology at Aventis (and predecessor companies), in Bridgewater, NJ. Dr. Gries has lead compound development across both early stage (with over 300 INDs) and late stage (13 NDAs, 7 ANDAs) and across a broad set of disease areas including Oncology, Inflammation and Pain, CNS, Metabolism, Cardio-Renal, Anti-Infectives (including HIV and HCV), Dermatology, Ophthalmology, Genito-Urinary and GastroEnterology.
As a business executive, Dr, Gries helped create 9 companies (2 of which are now public) via 26 assets acquisition and led them early on, in a Venture Capital company specialized in the creation and incubation of Biotechnology startups. He has extensive licensing experience from both Roche (member of the licensing committee) and Aventis (Oncology and CNS licensing committee) and Alcon (Board level). Dr. Gries also served on private companies and Not For Profits Boards of Directors.
Dr. Gries is the author of more than 30 papers and communications. He has been a fellow of the American College of Clinical Pharmacology since 2001, served on its Finance Committee and on its Board of Regents, and is a reviewer for JCP. He is also a member of ASCPT, ASCO, and AAO.
Dr. Gries received his PhD in Pharmacokinetics and applied mathematics, and his PharmD from the University Rene Descartes (Paris V) in France, his PhD in Analytical chemistry and his Master in Statistics, Computer sciences and Epidemiology from University Paris XI, and his MBA from the Wharton School at the University of Pennsylvania.He completed his post doctoral training at the University of California, San Francisco.Message Presenter
Covance, with headquarters in Princeton, New Jersey, is one of the world’s largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion and more than 12,000 employees in more than 60 countries. Covance has the people, processes, client service, and global resource capabilities to respond to biotechnology and Pharmaceutical clients’ toughest drug development challenges.